(ELV) Elevance Health - Ratings and Ratios
Health Plans, Pharmacy Services, Specialty Insurance, Care Management
Dividends
| Dividend Yield | 2.07% |
| Yield on Cost 5y | 2.29% |
| Yield CAGR 5y | 14.45% |
| Payout Consistency | 100.0% |
| Payout Ratio | 22.3% |
| Risk via 10d forecast | |
|---|---|
| Volatility | 28.2% |
| Value at Risk 5%th | 43.8% |
| Relative Tail Risk | -5.72% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.40 |
| Alpha | -22.84 |
| CAGR/Max DD | -0.26 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.490 |
| Beta | 0.149 |
| Beta Downside | 0.094 |
| Drawdowns 3y | |
|---|---|
| Max DD | 50.38% |
| Mean DD | 18.14% |
| Median DD | 14.08% |
Description: ELV Elevance Health December 03, 2025
Elevance Health Inc. (NYSE: ELV) operates as a diversified health-benefits company in the United States, organized into four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. The firm delivers a broad portfolio that includes commercial, Medicare, Medicaid and Federal Employee Program (FEP) health plans under the Anthem Blue Cross & Blue Shield, Wellpoint and Carelon brands, as well as supplemental products such as dental, vision, stop-loss and specialty insurance.
Beyond traditional insurance, Elevance runs a sizable pharmacy-services business (CarelonRx) that offers home delivery, specialty pharmacy, formulary management, rebate administration and infusion services. Its Carelon Services arm provides integrated care-management capabilities-behavioral health, utilization management, virtual care, payment integrity, and data-analytics platforms (HealthOS)-to support both internal plans and external payers.
Key performance indicators from the most recent fiscal year (2023) show total revenue of roughly $145 billion, enrollment of about 57 million members, and a medical loss ratio (MLR) hovering near 84 %, reflecting the industry-wide pressure from rising drug costs and inflationary health-care spending. Primary sector drivers include the aging U.S. population (projected Medicare enrollment growth of ~4 % per year through 2030) and regulatory trends such as the ongoing implementation of the Inflation Reduction Act, which caps drug price increases for Medicare beneficiaries.
For a deeper quantitative breakdown, the ValueRay platform provides granular metrics and scenario analysis to help assess Elevance’s valuation under different market assumptions.
Piotroski VR‑10 (Strict, 0-10) 7.0
| Net Income (5.53b TTM) > 0 and > 6% of Revenue (6% = 11.69b TTM) |
| FCFTA 0.03 (>2.0%) and ΔFCFTA 2.32pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 11.75% (prev 7.58%; Δ 4.18pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.04 (>3.0%) and CFO 4.91b <= Net Income 5.53b (YES >=105%, WARN >=100%) |
| Net Debt (-7.78b) to EBITDA (10.02b) ratio: -0.78 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.56 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (225.8m) change vs 12m ago -3.13% (target <= -2.0% for YES) |
| Gross Margin 50.46% (prev 27.94%; Δ 22.52pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 162.8% (prev 149.3%; Δ 13.51pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 6.16 (EBITDA TTM 10.02b / Interest Expense TTM 1.38b) >= 6 (WARN >= 3) |
Altman Z'' 3.11
| (A) 0.19 = (Total Current Assets 63.78b - Total Current Liabilities 40.88b) / Total Assets 122.75b |
| (B) 0.29 = Retained Earnings (Balance) 35.59b / Total Assets 122.75b |
| (C) 0.07 = EBIT TTM 8.48b / Avg Total Assets 119.64b |
| (D) 0.45 = Book Value of Equity 35.05b / Total Liabilities 78.67b |
| Total Rating: 3.11 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 72.47
| 1. Piotroski 7.0pt |
| 2. FCF Yield 5.54% |
| 3. FCF Margin 1.93% |
| 4. Debt/Equity 0.02 |
| 5. Debt/Ebitda -0.78 |
| 6. ROIC - WACC (= 2.84)% |
| 7. RoE 12.91% |
| 8. Rev. Trend 95.77% |
| 9. EPS Trend 8.29% |
What is the price of ELV shares?
Over the past week, the price has changed by +0.84%, over one month by +4.62%, over three months by +8.47% and over the past year by -14.79%.
Is ELV a buy, sell or hold?
- Strong Buy: 13
- Buy: 5
- Hold: 4
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the ELV price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 386.1 | 16.7% |
| Analysts Target Price | 386.1 | 16.7% |
| ValueRay Target Price | 328.1 | -0.8% |
ELV Fundamental Data Overview November 27, 2025
P/E Trailing = 13.6974
P/E Forward = 11.9048
P/S = 0.3887
P/B = 1.7003
P/EG = 0.9757
Beta = 0.532
Revenue TTM = 194.82b USD
EBIT TTM = 8.48b USD
EBITDA TTM = 10.02b USD
Long Term Debt = 31.17b USD (from longTermDebt, last quarter)
Short Term Debt = 929.0m USD (from shortTermDebt, last quarter)
Debt = 929.0m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -7.78b USD (from netDebt column, last quarter)
Enterprise Value = 67.94b USD (75.72b + Debt 929.0m - CCE 8.71b)
Interest Coverage Ratio = 6.16 (Ebit TTM 8.48b / Interest Expense TTM 1.38b)
FCF Yield = 5.54% (FCF TTM 3.77b / Enterprise Value 67.94b)
FCF Margin = 1.93% (FCF TTM 3.77b / Revenue TTM 194.82b)
Net Margin = 2.84% (Net Income TTM 5.53b / Revenue TTM 194.82b)
Gross Margin = 50.46% ((Revenue TTM 194.82b - Cost of Revenue TTM 96.51b) / Revenue TTM)
Gross Margin QoQ = 14.18% (prev 15.62%)
Tobins Q-Ratio = 0.55 (Enterprise Value 67.94b / Total Assets 122.75b)
Interest Expense / Debt = 37.78% (Interest Expense 351.0m / Debt 929.0m)
Taxrate = 15.58% (219.0m / 1.41b)
NOPAT = 7.16b (EBIT 8.48b * (1 - 15.58%))
Current Ratio = 1.56 (Total Current Assets 63.78b / Total Current Liabilities 40.88b)
Debt / Equity = 0.02 (Debt 929.0m / totalStockholderEquity, last quarter 43.95b)
Debt / EBITDA = -0.78 (Net Debt -7.78b / EBITDA 10.02b)
Debt / FCF = -2.07 (Net Debt -7.78b / FCF TTM 3.77b)
Total Stockholder Equity = 42.87b (last 4 quarters mean from totalStockholderEquity)
RoA = 4.51% (Net Income 5.53b / Total Assets 122.75b)
RoE = 12.91% (Net Income TTM 5.53b / Total Stockholder Equity 42.87b)
RoCE = 11.45% (EBIT 8.48b / Capital Employed (Equity 42.87b + L.T.Debt 31.17b))
RoIC = 9.70% (NOPAT 7.16b / Invested Capital 73.75b)
WACC = 6.87% (E(75.72b)/V(76.65b) * Re(6.56%) + D(929.0m)/V(76.65b) * Rd(37.78%) * (1-Tc(0.16)))
Discount Rate = 6.56% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: -100.0 | Cagr: -2.14%
[DCF Debug] Terminal Value 77.92% ; FCFE base≈2.61b ; Y1≈2.54b ; Y5≈2.57b
Fair Price DCF = 205.3 (DCF Value 45.63b / Shares Outstanding 222.2m; 5y FCF grow -3.53% → 3.0% )
EPS Correlation: 8.29 | EPS CAGR: 4.35% | SUE: 1.95 | # QB: 1
Revenue Correlation: 95.77 | Revenue CAGR: 10.49% | SUE: 1.33 | # QB: 5
EPS next Quarter (2026-03-31): EPS=10.86 | Chg30d=-1.357 | Revisions Net=-9 | Analysts=16
EPS next Year (2026-12-31): EPS=27.39 | Chg30d=-3.179 | Revisions Net=-18 | Growth EPS=-8.6% | Growth Revenue=+3.6%
Additional Sources for ELV Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle